Previous Close | 186.55 |
Open | 188.19 |
Bid | 191.86 x 800 |
Ask | 192.75 x 1200 |
Day's Range | 186.33 - 193.54 |
52 Week Range | 162.72 - 236.90 |
Volume | |
Avg. Volume | 1,013,626 |
Market Cap | 31.107B |
Beta (5Y Monthly) | 0.81 |
PE Ratio (TTM) | 56.60 |
EPS (TTM) | 3.40 |
Earnings Date | Aug 28, 2024 - Sept 02, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 221.21 |
Veeva Systems (NYSE: VEEV) today revealed that targeted pre-launch scientific outreach maximizes medical affairs teams' impact on treatment adoption in the latest Veeva Pulse Field Trends Report. The analysis shows biopharmas investing in pre-launch scientific activities and prioritizing congresses gain 40% faster treatment adoption than those that invested less. Early-career experts are also more open to digital engagement and four times more likely to start patients on a new treatment.
Veeva Systems (VEEV) closed the most recent trading day at $184.25, moving -1.32% from the previous trading session.
Veeva Systems' (VEEV) Vault EDC is likely to aid the CRO in delivering a better experience to patients, research sites and sponsors.